Patent RE39866 was granted and assigned to Telik (company) on October, 2007 by the United States Patent and Trademark Office.
Modulation of the activity of the insulin receptor, enhancement of glucose uptake by cells, and other effects significant in the control and management of diabetes are accomplished using compounds of the formulawhereineach A is independently a proton-accepting substituent;each R is independently a noninterfering substituent;n is 0, 1, or 2; andeach linker is independently an isostere of —NHCONH— or of —N═N— or of —NHCO—.